Lead Product(s): Tedopi,Undisclosed
Therapeutic Area: Oncology Product Name: OSE-2101
Highest Development Status: Undisclosed Product Type: Vaccine
Partner/Sponsor/Collaborator: European Investment Bank
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement February 15, 2021
This loan will help expand the clinical development of Tedopi® in combination with a checkpoint inhibitor in additional cancer indications.